The present invention is related to use of marimastat or a pharmaceutically acceptable salt, solvate or polymorph thereof in preventing or treating epileptogenesis in a subject that suffered a brain insult. Said brain insult is a stroke, traumatic brain injury, or a result of status epilepticus, evoked by structural or metabolic reasons. Marimastat or a pharmaceutically acceptable salt thereof is administered preferably within the first 24 hours after induction of epileptogenesis.
The Nencki Institute is a co-applicant of the patent with University of Warsaw. The Institute is the leader of patent protection and commercialization related activities.
The invention is the subject of a license agreement with Pikralida Sp. z o.o. .
For more information contact Technology Transfer Office.